“Patients with solid tumors with fibroblast growth receptor genetic alterations demonstrated tumor shrinkage with the novel agent BGJ398, according to study results presented at the American Association for Cancer Research Annual Meeting.
“The benefit was particularly apparent among patients with FGFR3-mutated urothelial cancer.
“ ‘An emerging concept in cancer treatment is to try to treat cancers with a genetically defined alteration with an inhibitor of the receptor tyrosine kinase that drives the cancer growth,’ Lecia V. Sequist, MD, MPH, associate professor of medicine at Harvard Medical School and Massachusetts General Hospital, said during a press conference. ‘This clinical study enrolled patients with many different tumor types. There are many types of tumors that have alterations of FGFR. Importantly, in contrast to other, more promiscuous multitargeted kinase inhibitors that happen to inhibit FGFR as one of their targets, BGJ398 has really no significant inhibition of the VEGF family of receptors.’ ”